Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...
The cutting-edge technology used in COVID-19 shots may lead to new treatments for other diseases. But some conservatives are ...
Fintel reports that on March 13, 2025, Citigroup initiated coverage of Moderna (NasdaqGS:MRNA) with a Neutral recommendation.
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...
On the five-year anniversary of the Covid pandemic, a Times reporter, Apoorva Mandavilli, looks back at the success of, and the backlash to, the mRNA vaccine. There’s no question that this ...
Vaccine skeptics have long-since leveraged the rapid roll out of mRNA vaccines to add fuel to heated arguments surrounding vaccine safety. As a result, a growing share of the public is wary of ...
MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by ...
The trial would combine standard surgery and chemotherapy treatments — which are the standard of care for pancreatic cancer — with a customized mRNA vaccine. Each vaccine would be designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback